Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldoxorubicin + ALT-803 + ETBX-011 + GI-4000 + haNK + avelumab + bevacizumab + capecitabine + cyclophosphamide + fluorouracil + leucovorin + nab-paclitaxel + omega-3-acid ethyl esters + oxaliplatin
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a complex **clinical study drug combination**. It contains: - **aldoxorubicin** (an albumin-binding prodrug of doxorubicin, cytotoxic agent) - **ALT-803** (N-803, an interleukin-15 superagonist immunotherapy/cytokine agonist) - **ETBX-011** (therapeutic cancer vaccine, specific platform for targeted immunization, e.g., against specific tumor antigens) - **GI-4000** (therapeutic vaccine targeting RAS mutations) - **haNK** (engineered natural killer cell therapy) - **avelumab** (PD-L1-targeted monoclonal antibody, immune checkpoint inhibitor) - **bevacizumab** (VEGF inhibitor angiogenesis inhibitor monoclonal antibody) - **capecitabine** (oral prodrug of 5-fluorouracil, antimetabolite, cytotoxic agent) - **cyclophosphamide** (alkylating agent chemotherapy) - **fluorouracil** (antimetabolite chemotherapy) - **leucovorin** (used as rescue agent and to enhance 5FU efficacy, modulates folate metabolism) - **nab-paclitaxel** (nanoparticle albumin-bound formulation of paclitaxel, microtubule inhibitor) - **omega-3-acid ethyl esters** (dietary supplement for triglyceridemia, anti-inflammatory/adjunctive in oncology settings) - **oxaliplatin** (platinum-based alkylating agent chemotherapy) This extensive regimen is predominantly experimental, evaluated in clinical trials for **advanced/refractory cancer**, especially refractory solid tumors including colorectal and pancreatic cancer. The combination targets **multiple tumor and immune pathways**, involving cytotoxic agents, immune checkpoint inhibitors, angiogenesis inhibitors, cytokine therapies, cancer vaccines, cell therapies, and metabolic adjuncts, with the intent to overcome tumor immune resistance and exploit non-overlapping mechanisms.
- Brand names
- Bexmaroneothers
- Other names
- aldoxorubicinN-803N803N 803ALT-803ALT803ALT 803QUILT-3.032 (for combination use)GI-4000GI4000GI 4000haNKavelumabbevacizumabcapecitabinecyclophosphamidefluorouracilleucovorinnab-paclitaxelomega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl estersoxaliplatin
02
Targets
mutRAS (Mutant RAS neoantigen peptides)TS (Thymidylate synthase)IL2RB (IL-2 receptor beta chain)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)DNATUBB (Tubulin (alpha and beta subunits))IgG1 Fc (Immunoglobulin G1 Fc region)
Beyond the preview
Go deeper on aldoxorubicin + ALT-803 + ETBX-011 + GI-4000 + haNK + avelumab + bevacizumab + capecitabine + cyclophosphamide + fluorouracil + leucovorin + nab-paclitaxel + omega-3-acid ethyl esters + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldoxorubicin + ALT-803 + ETBX-011 + GI-4000 + haNK + avelumab + bevacizumab + capecitabine + cyclophosphamide + fluorouracil + leucovorin + nab-paclitaxel + omega-3-acid ethyl esters + oxaliplatin.